Abstract
Current front-line treatment for NSCLC includes PD1/PDL1 checkpoint inhibitors (CPI) alone or in combination with chemotherapy. Second line treatment approach is an unmet need, mainly limited to Docetaxel, and the utility of CPI is an open question. Here we report preliminary data of cohort 1 of the REPLAY trial that assess the efficacy of pembrolizumab (pembro) re-challenge.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
